Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer—The BRAIN Study
Article in Cancers (February 2024)
The most recent citing publications are shown below. View all 74 publications that cite this research output on Dimensions.
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
Article in Cancers (January 2023)
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Article in npj Precision Oncology (October 2022)